Protective Efficacy of Multiple Epitope-Based Vaccine against Hyalomma anatolicum, Vector of Theileria annulata and Crimean-Congo Hemorrhagic Fever Virus

被引:5
|
作者
Nandi, Abhijit [1 ]
Manisha [1 ]
Solanki, Vandana [2 ]
Tiwari, Vishvanath [2 ]
Sajjanar, Basavaraj [3 ]
Sankar, Muthu [1 ]
Saini, Mohini [4 ]
Shrivastava, Sameer [3 ]
Bhure, S. K. [4 ]
Ghosh, Srikant [1 ]
机构
[1] ICAR Indian Vet Res Inst, Div Parasitol, Izatnagar 243122, India
[2] Cent Univ Rajasthan, Dept Biochem, Ajmer 305817, India
[3] ICAR Indian Vet Res Inst, Vet Biotechnol Div, Izatnagar 243122, India
[4] ICAR Indian Vet Res Inst, Div Biochem, Izatnagar 243122, India
关键词
Hyalomma anatolicum; in silico; multi-epitope peptide; peptide vaccine; protective efficacy; BOOPHILUS-MICROPLUS; TICK CONTROL; CATTLE TICK; ANTIGEN; PEPTIDE; RECOGNITION; STRATEGIES; PREDICTION; PROTEINS; BM86;
D O I
10.3390/vaccines11040881
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hyalomma anatolicum is the principal vector for Theileria annulata, T. equi, and T. Lestoquardi in animals and the Crimean-Congo hemorrhagic fever virus in humans. Due to the gradual loss of efficacy of the available acaricides against field tick populations, the development of phytoacaricides and vaccines has been considered the two most critical components of the integrated tick management strategies. In the present study, in order to induce both cellular and humoral immune responses in the host against H. anatolicum, two multi-epitopic peptides (MEPs), i.e., VT1 and VT2, were designed. The immune-stimulating potential of the constructs was determined by in silicoinvestigation on allergenicity (non-allergen, antigenic (0.46 and 1.0046)), physicochemical properties (instability index 27.18 and 35.46), as well as the interaction of constructs with TLRs by docking and molecular dynamics analysis. The immunization efficacy of the MEPs mixed with 8% Montanide(TM) gel 01 PR against H. anatolicum larvae was determined as 93.3% and 96.9% in VT1- and VT2-immunized rabbits, respectively. Against adults, the efficacy was 89.9% and 86.4% in VT1- and VT2-immunized rabbits, respectively. A significant (p < 0.001) reduction in the anti-inflammatory cytokine (IL-4) and significantly higher IgG response was observed in a VT1-immunized group of rabbits as compared with the response observed in the control group. However, in the case of the VT2-immunized rabbits, an elevated anti-VT2 IgG and pro-inflammatory cytokine (IL-2) (>30 fold) along with a decreased level of anti-inflammatory cytokine IL-4 (0.75 times) was noted. The efficacy of MEP and its potential immune stimulatory responses indicate that it might be useful for tick management.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Identification and characterization of vaccine candidates against Hyalomma anatolicum-Vector of Crimean-Congo haemorrhagic fever virus
    Manjunathachar, Haranahally Vasanthachar
    Kumar, Binod
    Saravanan, Buddhi Chandrasekaran
    Choudhary, Suman
    Mohanty, Ashok K.
    Nagar, Gaurav
    Chigure, Gajanan
    Kumar, Gandham V. P. P. S. Ravi
    de la Fuente, Jose
    Ghosh, Srikant
    TRANSBOUNDARY AND EMERGING DISEASES, 2019, 66 (01) : 422 - 434
  • [2] Vaccine potential of recombinant antigens of Theileria annulata and Hyalomma anatolicum anatolicum against vector and parasite
    Jeyabal, L.
    Kumar, Binod
    Ray, Debdatta
    Azahahianambi, Palavesam
    Ghosh, Srikanta
    VETERINARY PARASITOLOGY, 2012, 188 (3-4) : 231 - 238
  • [3] Development of a protective inactivated vaccine against Crimean-Congo hemorrhagic fever infection
    Berber, Engin
    Canakoglu, Nurettin
    Tonbak, Sukru
    Ozdarendeli, Aykut
    HELIYON, 2022, 7 (10)
  • [4] Crimean-Congo Hemorrhagic Fever Virus: Advances in Vaccine Development
    Tipih, Thomas
    Burt, Felicity Jane
    BIORESEARCH OPEN ACCESS, 2020, 9 (01): : 137 - 150
  • [5] Crimean-Congo Hemorrhagic Fever Virus: Progress in Vaccine Development
    Ozdarendeli, Aykut
    DIAGNOSTICS, 2023, 13 (16)
  • [6] Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
    Sergio E. Rodriguez
    Robert W. Cross
    Karla A. Fenton
    Dennis A. Bente
    Chad E. Mire
    Thomas W. Geisbert
    Scientific Reports, 9
  • [7] Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever
    Rodriguez, Sergio E.
    Cross, Robert W.
    Fenton, Karla A.
    Bente, Dennis A.
    Mire, Chad E.
    Geisbert, Thomas W.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [8] Probable vector of Crimean-Congo hemorrhagic fever virus; Hyalomma aegyptium : a systematic review and meta-analysis
    Sadeghi, Hamid
    Khoei, Saeideh Gholamzadeh
    Shahsavari, Sara
    Aslanimehr, Masoumeh
    Nikkhahi, Farhad
    Babaei, Abouzar
    Gheibi, Nematollah
    Bizhani, Behzad
    GERMS, 2024, 14 (01): : 45 - 62
  • [9] Crimean-Congo hemorrhagic fever virus vaccine: past, present, and future
    Behboudi, Emad
    Kakavandi, Ehsan
    Hamidi-Sofiani, Vahideh
    Ebrahimian, Arefeh
    Shayestehpour, Mohammad
    REVIEWS AND RESEARCH IN MEDICAL MICROBIOLOGY, 2022, 33 (02): : 109 - 116
  • [10] Development of Multi-epitope Based Subunit Vaccine Against Crimean-Congo Hemorrhagic Fever Virus Using Reverse Vaccinology Approach
    Md. Ashik Imran
    Md. Rubiath Islam
    Akash Saha
    Shahida Ferdousee
    Moshiul Alam Mishu
    Ajit Ghosh
    International Journal of Peptide Research and Therapeutics, 28